10% GDP to make India $10 trillion economy, end poverty by 2032: Amitabh Kant
India needs to grow at ten percent to become USD ten trillion economy and eliminate poverty by 2032, Niti Aayog Chief Executive Officer Amitabh Kant said Thursday.
New Delhi: India needs to grow at ten percent to become USD ten trillion economy and eliminate poverty by 2032, Niti Aayog Chief Executive Officer Amitabh Kant said Thursday.
The country's growth rate was 7.6 percent in 2015-16 and its economy worth USD 1.7 trillion.
In a presentation made during Civil Services Day function attended by Prime Minister Narendra Modi and large number of civil servants, he said a growth rate of ten percent would also help in creation of 175 millions jobs by 2032.
"Growing at 10 percent will transform India. India will be a USD 10 trillion economy with no poverty in 2032," his presentation reads.
The presentation was made on the status of implementation of reports of 'Group of Secretaries' formed by the Modi government. A total of eight Group of Secretaries were formed in December last year on focus areas.
"These eight groups had officers from different ministries. Further, there were 16 groups of Joint Secretaries who simultaneously worked on their focus areas. We cut across silos so that we can act on the eight themes and act as agent of change," Kant said.
He said that current seven percent growth rate would make India only a USD six trillion economy by 2032 and would still leave 5-6 percent of population Below Poverty Line (BPL).
The groups has decided on sub-themes, Some of its recommendation have been acted on whereas a road map has been suggested for the rest to achieve intended target.
Under the sub-theme "accelerated growth", Kant said there will be Rs two lakh crore worth investment in roads and railways in Financial Year 2017. It intends to complete 10,000 km of road project during the same period.
LPG connections to below poverty line women through Pradhan Mantri Ujjwala Yojana and promotion of medical tourism are other action points suggested by the group under "health and pharma" category.